Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS
· Delayed Price · Currency is USD
0.120
0.00 (0.00%)
At close: Apr 29, 2026
Eloxx Pharmaceuticals Employees
Eloxx Pharmaceuticals had 10 employees as of December 31, 2025. The number of employees decreased by 8 or -44.44% compared to the previous year.
Employees
10
Change
-8
Growth
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$599,500
Market Cap
608.63K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 33 |
| Bio-Path Holdings | 1 |
| Altamira Therapeutics | 11 |
| Hepion Pharmaceuticals | 2 |
| Iterum Therapeutics | 9 |
Eloxx Pharmaceuticals News
- 1 year ago - Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases - GlobeNewsWire
- 2 years ago - Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases - Business Wire
- 2 years ago - Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 years ago - Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome - GlobeNewsWire